Gambro Dialysatoren GmbH
11
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
27.3%
3 terminated/withdrawn out of 11 trials
72.7%
-13.8% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Effect of HCO1100 on Cardiovascular Function
Role: collaborator
High Cut Off Dialysis in Systemic Inflammatory Response Syndrome Patients After Cardiac Surgery
Role: collaborator
Improvement of EPO-resistance in Hemodialysis Patients With Chronic Inflammation by High Cut-off Hemodialysis
Role: collaborator
Myoglobin Removal by High Cut-off CVVHD
Role: collaborator
PERCI- Medium Cut Off (MCO)
Role: collaborator
Clinical Assessment of a New Catheter Surface Coating With Antimicrobial Properties
Role: collaborator
Permeability Enhancement to Reduce Chronic Inflammation
Role: collaborator
Ex Vivo Microbiological Assessment of an Anti-biofilm Catheter in Acute Dialysis Application
Role: collaborator
Performance Comparison of Revaclear With Larger Dialyzer
Role: collaborator
High Cut-Off Continuous Veno-venous Hemodialysis (CVVHD) in Patients Treated for Acute Renal Failure After Systemic Inflammatory Response Syndrome (SIRS)/Septic Shock
Role: collaborator
High-cutoff Hemodialyzer to Reduce Chronic Inflammation in Hemodialysis Patients
Role: collaborator
All 11 trials loaded